RLMD
Relmada Therapeutics, Inc.·Healthcare
7.29
4.205%(−0.32)
Market ClosedLast Updated: — ET
52W L: $0.2752W H: $7.94
RLMD NEWS
zacks.com
Apr 2
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, CPRX, TBPH, RLMD and AVTX may prove to be good additions to one's portfolio.
zacks.com
Mar 26
Wall Street Analysts Predict a 92.19% Upside in Relmada Therapeutics (RLMD): Here's What You Should Know
The mean of analysts' price targets for Relmada Therapeutics (RLMD) points to a 92.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
defenseworld.net
Mar 25
Financial Contrast: Alseres Pharmaceuticals (OTCMKTS:ALSE) vs. Relmada Therapeutics (NASDAQ:RLMD)
Relmada Therapeutics (NASDAQ: RLMD - Get Free Report) and Alseres Pharmaceuticals (OTCMKTS:ALSE - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations. Insider and Institutional Ownership 45.2% of Relmada Therapeutics
seekingalpha.com
Mar 19
Relmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call Transcript
Relmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call Transcript
globenewswire.com
Mar 19
Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
CORAL GABLES, Fla., March 19, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today reported audited financial results for the fourth quarter and full year ended December 31, 2025 and provided a corporate update highlighting significant progress across its pipeline.
zacks.com
Mar 12
RLMD Stock Surges 42% in a Week: Here's What You Should Know
Relmada Therapeutics jumps 42% in a week after reporting encouraging efficacy and safety data from a mid-stage bladder cancer study of NDV-01, simultaneously sharing phase III plans.
